$1.42
1.43% yesterday
Nasdaq, Nov 07, 10:00 pm CET
ISIN
US58468P2065
Symbol
MNOV

MediciNova, Inc. Stock price

$1.42
+0.17 13.15% 1M
-0.07 4.70% 6M
-0.68 32.38% YTD
-0.15 9.55% 1Y
-0.76 34.86% 3Y
-4.60 76.41% 5Y
-1.85 56.57% 10Y
-9.53 87.03% 20Y
Nasdaq, Closing price Fri, Nov 07 2025
+0.02 1.43%
ISIN
US58468P2065
Symbol
MNOV
Industry

Key metrics

Basic
Market capitalization
$68.7m
Enterprise Value
$34.4m
Net debt
positive
Cash
$34.3m
Shares outstanding
49.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
528.2 | -
EV/Sales
264.7 | -
EV/FCF
negative
P/B
1.5
Financial Health
Equity Ratio
94.0%
Return on Equity
-21.1%
ROCE
-21.4%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$130.0k | $0.0
EBITDA
$-10.1m | -
EBIT
$-10.1m | $-30.2m
Net Income
$-9.0m | $-20.0m
Free Cash Flow
$-10.1m
Growth (TTM | estimate)
Revenue
-87.0% | -
EBITDA
-51.1% | -
EBIT
-51.0% | -138.4%
Net Income
-65.4% | -81.1%
Free Cash Flow
-17.5%
Margin (TTM | estimate)
Gross
-
EBITDA
-7,488.3% | -
EBIT
-7,503.6%
Net
-6,647.9% | -
Free Cash Flow
-7,469.5%
More
EPS
$-0.2
FCF per Share
$-0.2
Short interest
0.3%
Employees
13
Rev per Employee
$0.0
Show more

Is MediciNova, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.

MediciNova, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a MediciNova, Inc. forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a MediciNova, Inc. forecast:

Buy
88%
Hold
13%

Financial data from MediciNova, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
0.13 0.13
87% 87%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 4.28 4.28
19% 19%
3,292%
- Research and Development Expense 5.96 5.96
46% 46%
4,585%
-10 -10
51% 51%
-7,754%
- Depreciation and Amortization 0.02 0.02
0% 0%
15%
EBIT (Operating Income) EBIT -10 -10
51% 51%
-7,769%
Net Profit -8.95 -8.95
65% 65%
-6,885%

In millions USD.

Don't miss a Thing! We will send you all news about MediciNova, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

MediciNova, Inc. Stock News

Neutral
GlobeNewsWire
one day ago
LA JOLLA, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), announces that the company has been selected as a winner of the “Contract Research and Development Innovation Award” at the Fifth Annual BioTech Breakthrough Awards.
Neutral
GlobeNewsWire
8 days ago
Study published in the Journal of Atherosclerosis and Thrombosis demonstrates tipelukast (MN-001 and its metabolite MN-002) has influence on cholesterol metabolism in patients Study published in the Journal of Atherosclerosis and Thrombosis demonstrates tipelukast (MN-001 and its metabolite MN-002) has influence on cholesterol metabolism in patients
Neutral
GlobeNewsWire
about one month ago
LA JOLLA, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), announces that Yuichi Iwaki, M.D., Ph.D., President and CEO, and David H. Crean, Ph.D., Chief Business Officer, will present a corporate overview at the LD Micr...
More MediciNova, Inc. News

Company Profile

MediciNova, Inc. is a biopharmaceutical company, which engages in the acquisition and development of small molecule therapeutics for the treatment of serious diseases for the treatment of diseases with unmet medical need. Its development pipeline consists of clinical-stage compounds for the treatment of acute exacerbations of asthma and COPD, progressive multiple sclerosis, methamphetamine addiction, neuropathic pain, asthma, interstitial cystitis, and solid tumor cancers. The company was founded by Yuichi Iwaki on September 26, 2000 and is headquartered in La Jolla, CA.

Head office United States
CEO Yuichi Iwaki
Employees 13
Founded 2000
Website medicinova.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today